Literature DB >> 1432035

Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse.

J K Lee1, R A Sobel, E A Chiocca, T S Kim, R L Martuza.   

Abstract

To develop a reproducible in vivo model for the growth of human acoustic neuromas and neurofibromas, we implanted tumor specimens (6 acoustic neuromas; 4 neurofibromas; 3 schwannomas arising in skin and soft tissues) from 13 different patients into the subrenal capsules of 67 nude mice and sciatic nerves of 64 nude mide. The animals were anesthetized and the tumors were microscopically implanted. Serial tumor volumes were determined at intervals up to 2 months by reopening the incision and directly measuring the tumor size with a micrometer. The percentages of acoustic neuromas that survived or grew were 57.1% in the subrenal capsule and 88.9% in the sciatic nerves; the percentages of neurofibromas that survived and grew were 50% in the subrenal capsule and 70% in the sciatic nerves; and the percentages of schwannomas that survived and grew were 57.1% in the subrenal capsule and 94.1% in the sciatic nerve. Tumors in the sciatic nerve also survived and grew for a longer period than those in the subrenal capsules. Tumor enlargement and stability correlated with neovascularity. At 1 or 2 months after engraftment, the tumors showed histologic appearances similar to the original tumors and immunohistochemical analysis of cryostat sections demonstrated staining of the tumors, but not the host mouse tissues for human beta 2-microglobulin, a species-specific marker. Furthermore, analysis of genomic DNA from implanted tumors revealed its human origin. We conclude that human acoustic neuromas, neurofibromas and schwannomas are readily grown in two sites in nude mice and that they retain their morphologic features and genomic identities. These tumors grow better and more consistently in the sciatic nerve than in the subrenal capsule. These are useful model systems for studying tumor growth and cellular modulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432035     DOI: 10.1007/bf00177613

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma.

Authors:  B R Seizinger; R L Martuza; J F Gusella
Journal:  Nature       Date:  1986 Aug 14-20       Impact factor: 49.962

2.  Genetics of susceptibility of rats to trigeminal schwannomas induced by neonatal administration of N-ethyl-N-nitrosourea.

Authors:  M Naito; A Ito; H Aoyama
Journal:  J Natl Cancer Inst       Date:  1985-01       Impact factor: 13.506

3.  An experimental model for selective production of neoplasms of the peripheral nervous system.

Authors:  R H Denlinger; A Koestner; J A Swenberg
Journal:  Acta Neuropathol       Date:  1973-02-19       Impact factor: 17.088

4.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

5.  Major histocompatibility complex molecule expression in the human central nervous system: immunohistochemical analysis of 40 patients.

Authors:  R A Sobel; M B Ames
Journal:  J Neuropathol Exp Neurol       Date:  1988-01       Impact factor: 3.685

6.  Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Authors:  A Medhkour; M Van Roey; R A Sobel; H J Fingert; J Lee; R L Martuza
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

7.  Genetics in neuro-oncology.

Authors:  R L Martuza
Journal:  Clin Neurosurg       Date:  1983

8.  The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ.

Authors:  R A Sobel; B W Blanchette; A K Bhan; R B Colvin
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

9.  Growth of human schwannomas in the subrenal capsule of the nude mouse.

Authors:  J K Lee; T S Kim; E A Chiocca; A Medhkour; R L Martuza
Journal:  Neurosurgery       Date:  1990-04       Impact factor: 4.654

10.  Studies of Schwann cell proliferation. III. Evidence for the surface localization of the neurite mitogen.

Authors:  J L Salzer; R P Bunge; L Glaser
Journal:  J Cell Biol       Date:  1980-03       Impact factor: 10.539

View more
  7 in total

1.  Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells.

Authors:  D Muir; D Neubauer; I T Lim; A T Yachnis; M R Wallace
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.

Authors:  Nicolas-Xavier Bonne; Jérémie Vitte; Fabrice Chareyre; Gevorg Karapetyan; Vazgen Khankaldyyan; Karo Tanaka; Rex A Moats; Marco Giovannini
Journal:  J Neurooncol       Date:  2016-05-13       Impact factor: 4.130

3.  Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Authors:  Maria Demestre; Jan Herzberg; Nikola Holtkamp; Christian Hagel; David Reuss; Reinhard E Friedrich; Lan Kluwe; Andreas Von Deimling; Victor-F Mautner; Andreas Kurtz
Journal:  J Neurooncol       Date:  2009-11-17       Impact factor: 4.130

4.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

5.  Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Authors:  Xing Gao; Yingchao Zhao; Anat O Stemmer-Rachamimov; Hao Liu; Peigen Huang; ShanMin Chin; Martin K Selig; Scott R Plotkin; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

6.  Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

Authors:  Hon Kit Wong; Johanna Lahdenranta; Walid S Kamoun; Annie W Chan; Andrea I McClatchey; Scott R Plotkin; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

7.  Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.

Authors:  Dusica Babovic-Vuksanovic; Lydia Petrovic; Bruce E. Knudsen; Timothy B. Plummer; Joseph E. Parisi; Srdan Babovic; Jeffrey L. Platt
Journal:  J Biomed Biotechnol       Date:  2004
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.